DMRA
The table below shows Damora Therapeutics, Inc.'s balance sheet line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $257.62M | $14.18M | $21.46M | $32.79M | $62.56M | $163.58M |
| Short-term investments | - | $11.69M | $11.69M | $27.44M | $37.63M | - |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $260.42M |
| $16.84M |
| $36.77M |
| $63.91M |
| $110.10M |
| $169.29M |
| Property, plant & equipment | $36.00K | $57.00K | $78.00K | $357.00K | $203.00K | - |
| Goodwill | - | - | - | - | - | - |
| Total assets | $260.53M | $17.13M | $38.23M | $73.19M | $122.22M | $171.60M |
| Accounts payable | $444.00K | $377.00K | $1.70M | $3.35M | $1.53M | $2.85M |
| Total current liabilities | $20.07M | $1.20M | $5.83M | $11.11M | $4.54M | $5.57M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $20.15M | $1.30M | $5.90M | $11.44M | $4.99M | $6.11M |
| Retained earnings | -$487.36M | -$277.52M | -$256.08M | -$217.74M | -$156.11M | -$104.36M |
| Total equity | $240.38M | $15.83M | $32.33M | $61.75M | $117.22M | $165.49M |